フルテキストURL Vasc_Health_Risk_Manag_11_265.pdf
著者 Saito, Yukihiro| Nakamura, Kazufumi| Akagi, Satoshi| Sarashina, Toshihiro| Ejiri, Kentaro| Miura, Aya| Ogawa, Aiko| Matsubara, Hiromi| Ito, Hiroshi|
キーワード apoptosis prostacyclin pulmonary arterial hypertension
備考 学位審査副論文
発行日 2015-05-14
出版物タイトル Vascular Health and Risk Management
11巻
出版者 Dove Medical Press
開始ページ 265
終了ページ 270
ISSN 1176-6344
NCID AA12158664
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
論文のバージョン publisher
PubMed ID 25999730
DOI 10.2147/VHRM.S50368
Web of Sience KeyUT 000210424400027
関連URL https://doi.org/10.2147/VHRM.S50368 http://ousar.lib.okayama-u.ac.jp/55246
JaLCDOI 10.18926/AMO/53519
フルテキストURL 69_3_129.pdf
著者 Akagi, Satoshi| Nakamura, Kazufumi| Matsubara, Hiromi| Ogawa, Aiko| Sarashina, Toshihiro| Ejiri, Kentaro| Ito, Hiroshi|
抄録 Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.
キーワード pulmonary arterial hypertension epoprostenol high-dose complications side effects
Amo Type Review
発行日 2015-06
出版物タイトル Acta Medica Okayama
69巻
3号
出版者 Okayama University Medical School
開始ページ 129
終了ページ 136
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 26101188
Web of Sience KeyUT 000356903000001
JaLCDOI 10.18926/AMO/30744
フルテキストURL fulltext.pdf
著者 Ogawa, Aiko| Emori, Tetsuro| Sumita, Wakako| Watanabe, Atsuyuki| Fujio, Hideki| Miyaji, Katsumasa| Ohe, Tohru|
抄録 <p>A 52-year-old obese woman was admitted to our institution for evaluation of dyspnea and pulmonary hypertension (PH). Polysomnography revealed severe obstructive sleep apnea (OSA) with an apnea hypopnea index of 99.8. Treatment with nocturnal continuous positive airway pressure (CPAP) resulted in correction of daytime hypoxemia, hypercapnia, and near-normalization of pulmonary artery pressure. To our knowledge, this is the most severe case of OSA-associated PH (approximately70 mmHg) reported to date, and it was successfully treated with nocturnal CPAP. This case demonstrates that OSA should be considered and polysomnography performed in all patients with PH, irrespective of severity, and that nocturnal CPAP has therapeutic effects on both OSA and daytime PH.</p>
キーワード continuous positive airway pressure polysomnography secondary pulmonary hypertension sleep apnea syndrome
Amo Type Article
発行日 2006-06
出版物タイトル Acta Medica Okayama
60巻
3号
出版者 Okayama University Medical School
開始ページ 191
終了ページ 195
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 16838048
Web of Sience KeyUT 000238503600007